Tyrosine kinase inhibitor-responsive chronic myeloid leukaemia is associated with reduced OXPHOS capacity and mtDNA mutations likely contribute to this.

Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations

Period15 May 2024 → 17 May 2024
Event titleThe 5th Australian Cancer and Metabolism Meeting (ACMM 2024)
Event typeConference
LocationAdelaide, Australia, South AustraliaShow on map
Degree of RecognitionNational

Keywords

  • Tyrosine
  • Kinase
  • inhibitor-responsive
  • CML
  • Chronic Myeloid Leukaemia
  • OXPHOS
  • mtDNA
  • mutation